Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cance...(e. To learn more about Lilly's commitme...),Health

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

P-LLY

GEMZAR(R) (gemcitabine HCl for injection), Lilly

This press release contains forward-looking statements about the potential of GEMZAR for the treatment of cervical cancer and reflects Lilly's current beliefs. However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development, commercialization, and regulatory review. There is no guarantee that the products will receive additional regulatory approvals. There is also no guarantee that the products will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(1) World Health Organization. Vaccine research and development - Vaccines against Human Papillomavirus. Available at: http://www.who.int/vaccines/en/hpvrd.shtml. Accessed May 1, 2009.

(2) Duenas A, Zarba JJ, Alcedo JC, et al: Phase III Randomized Comparison Of Concurrent Gemcitabine, Cisplatin, And Radiation Followed By Adjuvant Gemcitabine And Cisplatin Versus Concurrent
'/>"/>